Regular Articles
NADPH Oxidase-Derived Overproduction of Reactive Oxygen Species Impairs Postischemic Neovascularization in Mice with Type 1 Diabetes

https://doi.org/10.2353/ajpath.2006.060042Get rights and content

We hypothesized that diabetes-induced oxidative stress may affect postischemic neovascularization. The response to unilateral femoral artery ligation was studied in wild-type or gp91phox-deficient control or type 1 diabetic mice or in animals treated with the anti-oxidant N-acetyl-l-cysteine (NAC) or with in vivo electrotransfer of a plasmid encoding dominant-negative Rac1 (50 μg) for 21 days. Postischemic neovascularization was reduced in diabetic mice in association with down-regulated vascular endothelial growth factor-A protein levels. In diabetic animals vascular endothelial growth factor levels and postischemic neovascularization were restored to nondiabetic levels by the scavenging of reactive oxygen species (ROS) by NAC administration or the inhibition of ROS generation by gp91phox deficiency or by administration of dominant-negative Rac1. Finally, diabetes reduced the ability of adherent bone marrow-derived mononuclear cells (BM-MNCs) to differentiate into endothelial progenitor cells. Treatment with NAC (3 mmol/L), apocynin (200 μmol/L), or the p38MAPK inhibitor LY333351 (10 μmol/L) up-regulated the number of endothelial progenitor cell colonies derived from diabetic BM-MNCs by 1.5-, 1.6-, and 1.5-fold, respectively (P < 0.05). In the ischemic hindlimb model, injection of diabetic BM-MNCs isolated from NAC-treated or gp91phox-deficient diabetic mice increased neovascularization by ∼1.5-fold greater than untreated diabetic BM-MNCs (P < 0.05). Thus, inhibition of NADPH oxidase-derived ROS overproduction improves the angiogenic and vasculogenic processes and restores postischemic neovascularization in type 1 diabetic mice.

Cited by (0)

Supported by the British Heart Foundation (Chair of Cardiology at King's College London to A.M.S.); Agence Nationale de la Recherche (young investigator grant JC05-45445 and 2005 Cardiovascular, Obesity, and Diabetes grant ANR-05-PCOD-028-01 to J.-S.S.); The Netherlands Organization for Health Research and Development (Agiko stipend 920-03-291 to B.M.); the Prof. Michaël-van Vloten Fund; and the European Commission (INSERM U689 is partner of the European Vascular Genomics Network, a Network of Excellence granted by contract no. LSHM-CT-2003-503254).

View Abstract